Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Catastrophic antiphospholipid syndrome.

Setu K Vora1, Ronald A Asherson, Doruk Erkan

  • 1Pulmonary Physicians of Norwich, Norwich, Connecticut, USA.

Journal of Intensive Care Medicine
|May 5, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prevalence and prognostic value of activated protein C resistance and anti-protein C antibodies in patients with aPLs: an APS ACTION Registry study.

Rheumatology (Oxford, England)·2026
Same author

Correction: Anti-β2GPI IgG display a broad reactivity against different β2GPI domains beyond domain 1: results from the APS ACTION and multi-center Italian cohorts.

Frontiers in immunology·2026
Same author

Anti-β2GPI IgG display a broad reactivity against different β2GPI domains beyond domain 1: results from the APS ACTION and multi-center Italian cohorts.

Frontiers in immunology·2026
Same author

Correction: A proteomic map of thromboinflammatory signatures in antiphospholipid syndrome: results from antiphospholipid syndrome alliance for clinical trials and international networking (APS ACTION) registry.

Frontiers in immunology·2026
Same author

Understanding antiphospholipid syndrome clinical phenotypes with the guidance of antiphospholipid antibody-related pathogenic mechanisms.

Current opinion in immunology·2026
Same author

Do ethnoracial differences exist among antiphospholipid antibody-positive patients with no other systemic autoimmune diseases: results from the APS ACTION registry.

Advances in rheumatology (London, England)·2026

Catastrophic antiphospholipid syndrome (APS) is a severe condition causing organ damage due to blood clots. Early diagnosis and treatment, including anticoagulation, are crucial for survival, though mortality remains high.

Area of Science:

  • Rheumatology
  • Hematology
  • Critical Care Medicine

Background:

  • Catastrophic antiphospholipid syndrome (APS) is a rare, life-threatening condition characterized by widespread thrombosis.
  • It involves multiple organ systems and is associated with antiphospholipid antibodies.

Purpose of the Study:

  • To review current knowledge on the etiopathogenesis, clinical manifestations, diagnosis, management, and prognosis of catastrophic APS.
  • To highlight the importance of early diagnosis and aggressive treatment strategies.

Main Methods:

  • Literature review of existing studies and clinical information on catastrophic APS.
  • Synthesis of data regarding diagnostic criteria, treatment options, and patient outcomes.

Main Results:

Related Experiment Videos

  • Catastrophic APS presents with rapid, multi-organ thrombotic events.
  • Treatment involves anticoagulation, corticosteroids, and potentially plasma exchange or IVIG.
  • Despite intensive care, mortality is high (48%), often due to cardiopulmonary failure.

Conclusions:

  • Early recognition and prompt, aggressive management are vital for improving outcomes in catastrophic APS.
  • Further research is needed to reduce the significant mortality associated with this syndrome.